Roche announced plans to acquire Piramed Limited, a privately-owned UK company focusing on therapeutics targeting PI3-kinase (PI3-K). Roche will spend $160 million on the acquisition, along with a $15 million milestone payment, due upon commencement of phase II clinical trials for the company’s oncology program. Through this acquisition, Roche’s R&D pipeline is strengthened by Piramed’s two major research programs targeting PI3-K-alpha in oncology and PI3K-delta in infla...